Registry for gastric and esophageal cancer treatments in Germany
Official title: Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy
Run by iOMEDICO AG · NCT04290806 · Data updated 2026-11-12
This study is collecting information on how patients in Germany with advanced esophageal and stomach cancers are treated to see how well different treatments work in real life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1900 (estimated) |
| Sponsor | iOMEDICO AG Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | December 4, 2019 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | January 28, 2026 |
| Trial ID | NCT04290806 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed stage IV esophageal, gastric, or gastroesophageal junction cancer who are planned for palliative systemic therapy.
✕Probably not a fit
Patients who are not receiving systemic therapy for their cancer will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The SAPHIR registry collects and analyzes data on the treatment of patients with metastatic esophageal, gastric, or gastroesophageal junction cancer in Germany. This national, observational study follows patients for up to two years, documenting their treatment regimens, patient characteristics, and health-related quality of life. By tracking therapeutic sequences and treatment changes, the registry aims to provide insights into real-world treatment practices and outcomes for these cancers.
Why it matters
Potential benefit: If successful, this registry could improve understanding of treatment effectiveness and patient outcomes for metastatic gastric and esophageal cancers.
How similar studies have gone: Other observational studies have successfully utilized registry approaches to improve treatment understanding and patient outcomes in oncology, suggesting potential for success in this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC * Planned palliative systemic first-line therapy * Age \>= 18 years * Signed informed consent (IC) * Patients answering questionnaires: IC before first therapy cycle * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle Exclusion Criteria: * No systemic therapy for ESCC, EAC, GAC or GEJAC
Where it's running
-
Multiple sites, Gemany
Multiple Locations, Germany Recruiting
Study contacts
- Study coordinator: Adrian Binninger
- Email: info@iomedico.com
- Phone: +49 761 152 42 - 0
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PLX-61639 for advanced SMARCA4-deficient solid tumors
This trial will test a daily oral drug called PLX-61639 in people with advanced or metastatic solid tumors that have a SMARCA4 loss and who have no other approved treatment options.
-
PF-08046876 for people with advanced solid tumors
This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.
-
Combination of OBP-301 and Pembrolizumab for Advanced Esophagogastric Cancer
This study is trying a new treatment combining OBP-301 and pembrolizumab to see if it can help people with advanced esophageal and gastric cancer who haven't responded well to previous immunotherapy.
-
Testing a new drug for advanced solid tumors
This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.
-
AI-powered tumor response assessment after preoperative treatment in stomach and gastroesophageal junction cancer
Researchers are testing whether an AI tool called DeepTRG can reliably measure how much cancer remains in tissue removed after preoperative therapy in stomach and GEJ cancer, without needing a human to correct the AI results.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.